CY1118789T1 - Χρηση 5α-ανδροστανο(αλκυλο)-3β,5-6β-τριολης σε παρασκευη νευροπροστατευτικων φαρμακων - Google Patents

Χρηση 5α-ανδροστανο(αλκυλο)-3β,5-6β-τριολης σε παρασκευη νευροπροστατευτικων φαρμακων

Info

Publication number
CY1118789T1
CY1118789T1 CY20171100375T CY171100375T CY1118789T1 CY 1118789 T1 CY1118789 T1 CY 1118789T1 CY 20171100375 T CY20171100375 T CY 20171100375T CY 171100375 T CY171100375 T CY 171100375T CY 1118789 T1 CY1118789 T1 CY 1118789T1
Authority
CY
Cyprus
Prior art keywords
alkyl
preparation
triolis
neurostructive
androstano
Prior art date
Application number
CY20171100375T
Other languages
English (en)
Inventor
Guangmei Yan
Haiyan Hu
Tiandong Leng
Hanfei Sang
Jingxia Zhang
Pengxin Qiu
Shujia Zhou
Jiesi Chen
Xiuhua You
Original Assignee
Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Cellprotek Pharmaceutical Co., Ltd. filed Critical Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Publication of CY1118789T1 publication Critical patent/CY1118789T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Γνωστοποιείται στην παρούσα εφεύρεση η χρήση 5α-ανδροστανο (αλκυλο)-3β,5-6β-τριόλης σε παρασκευή νευροπροστατευτικών φαρμάκων. Η ένωση έχει σημαντικές προστατευτικές επιδράσεις σε βλάβες των νευρώνων οι οποίες επάγονται από εγκεφαλική ισχαιμία, ισχαιμία νωτιαίου μυελού και υποξία, και δεν έχει καμία εμφανή τοξική παρενέργεια υπό την αποτελεσματική δόση αυτής.
CY20171100375T 2010-07-09 2017-03-27 Χρηση 5α-ανδροστανο(αλκυλο)-3β,5-6β-τριολης σε παρασκευη νευροπροστατευτικων φαρμακων CY1118789T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010102241733A CN101884638B (zh) 2010-07-09 2010-07-09 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
PCT/CN2011/076967 WO2012003802A1 (zh) 2010-07-09 2011-07-08 5α-雄甾（烷）-3β，5，6β-三醇在制备神经元保护药物中的应用

Publications (1)

Publication Number Publication Date
CY1118789T1 true CY1118789T1 (el) 2018-03-07

Family

ID=43070839

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100375T CY1118789T1 (el) 2010-07-09 2017-03-27 Χρηση 5α-ανδροστανο(αλκυλο)-3β,5-6β-τριολης σε παρασκευη νευροπροστατευτικων φαρμακων

Country Status (21)

Country Link
US (2) US8809309B2 (el)
EP (1) EP2591785B1 (el)
JP (1) JP5681931B2 (el)
KR (1) KR101463477B1 (el)
CN (1) CN101884638B (el)
AU (1) AU2011276800B2 (el)
BR (1) BR112012031861B1 (el)
CA (1) CA2802133C (el)
CY (1) CY1118789T1 (el)
DK (1) DK2591785T3 (el)
ES (1) ES2620754T3 (el)
HR (1) HRP20170418T1 (el)
HU (1) HUE032159T2 (el)
LT (1) LT2591785T (el)
PL (1) PL2591785T3 (el)
PT (1) PT2591785T (el)
RS (1) RS55845B1 (el)
RU (1) RU2541093C2 (el)
SG (1) SG186135A1 (el)
SI (1) SI2591785T1 (el)
WO (1) WO2012003802A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101884638B (zh) 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
CN105012313B (zh) * 2014-04-25 2018-03-16 广州市赛普特医药科技股份有限公司 5α‑雄甾‑3β,5,6β‑三醇及其类似物在预防或治疗低压缺氧引起的高原病中的应用
CN102617685B (zh) * 2012-03-08 2014-01-22 广州市赛普特医药科技有限公司 雄甾-3β,5α,6β-三醇的晶型化合物及其制备方法
EP2653163A1 (en) * 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
CN104072564B (zh) 2013-03-28 2016-08-17 广州市赛普特医药科技股份有限公司 2β,3α,5α-三羟基-雄甾-6-酮及其制备方法与用途
CN109985049B (zh) * 2017-12-29 2022-02-22 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗脑小血管病的药物中的应用
CN113350359B (zh) * 2017-12-29 2022-08-16 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用
US11516173B1 (en) * 2018-12-26 2022-11-29 Snap Inc. Message composition interface

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191576A (en) * 1936-11-21 1940-02-27 Soc Of Chemical Ind 3,5,6-trihydroxy androstane and pregnane compounds
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US20070099880A1 (en) * 2003-11-24 2007-05-03 Blizzard Timothy A Estrogen receptor modulators
CN1557829A (zh) * 2004-01-19 2004-12-29 复旦大学 化合物5α-雄甾烷-1α,3β,17β-三醇17-醋酸酯和衍生物,及其制备方法
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
GB0711948D0 (en) * 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101683348B (zh) * 2008-09-23 2012-07-04 中山大学 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法

Also Published As

Publication number Publication date
RU2541093C2 (ru) 2015-02-10
AU2011276800A9 (en) 2013-11-21
DK2591785T3 (en) 2017-03-27
US20140329790A1 (en) 2014-11-06
JP2013529657A (ja) 2013-07-22
JP5681931B2 (ja) 2015-03-11
HUE032159T2 (en) 2017-09-28
CN101884638B (zh) 2011-11-09
KR101463477B1 (ko) 2014-11-19
KR20130038286A (ko) 2013-04-17
RS55845B1 (sr) 2017-08-31
BR112012031861B1 (pt) 2020-02-04
PT2591785T (pt) 2017-04-04
CN101884638A (zh) 2010-11-17
RU2012151400A (ru) 2014-08-20
US8809309B2 (en) 2014-08-19
SI2591785T1 (sl) 2017-07-31
AU2011276800A1 (en) 2013-01-10
CA2802133A1 (en) 2012-01-12
ES2620754T3 (es) 2017-06-29
EP2591785A1 (en) 2013-05-15
SG186135A1 (en) 2013-01-30
EP2591785B1 (en) 2017-01-04
US20130157993A1 (en) 2013-06-20
US9320743B2 (en) 2016-04-26
BR112012031861A2 (pt) 2016-11-08
HRP20170418T1 (hr) 2017-06-16
CA2802133C (en) 2014-01-14
EP2591785A4 (en) 2013-12-11
AU2011276800B2 (en) 2013-11-21
PL2591785T3 (pl) 2017-08-31
LT2591785T (lt) 2017-06-26
WO2012003802A1 (zh) 2012-01-12

Similar Documents

Publication Publication Date Title
CY1118789T1 (el) Χρηση 5α-ανδροστανο(αλκυλο)-3β,5-6β-τριολης σε παρασκευη νευροπροστατευτικων φαρμακων
CY1120297T1 (el) Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
WO2014127917A8 (en) Combination of vaccination and inhibition of the pd-1 pathway
CY1122671T1 (el) Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων
CY1126136T1 (el) Μεθοδοι θεραπειας της αρθριτιδας
CY1119005T1 (el) Ενωσεις τουμπουλυσινης, μεθοδοι παρασκευης και χρηση
CY1123811T1 (el) Κρυσταλλικη μορφη αναστολεα pde4
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
PH12015500243A1 (en) Glycoconjugation processes and compositions
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
MY197723A (en) Vaccine compositions for the prevention of dengue virus infection
CY1118323T1 (el) Ρυθμιστες του ηπατικου υποδοχεα χ
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica